[Form 4] ARTIVION, INC. Insider Trading Activity

Rhea-AI Filing Summary

Artivion, Inc. (AORT) reported insider share transactions by its Chief Commercial Officer on Form 4. On November 14, 2025 and November 17, 2025, the officer exercised stock options to acquire 6,393 and 6,394 shares of common stock, respectively, at an exercise price of $29.62 per share. On the same dates, the officer sold the same numbers of shares at prices of $44.67 and $45.17 per share. After these transactions, the officer directly owned 198,842 shares of Artivion common stock. The filing notes that the option exercises and related sales were carried out under a Rule 10b5-1 trading plan adopted on August 14, 2025, and that the options originally began vesting on March 5, 2020.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Davis John E

(Last) (First) (Middle)

1655 ROBERTS BLVD., NW

(Street)

KENNESAW GA 30144

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ARTIVION, INC. [ AORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/14/2025		M		6,393(1)	A	$29.62	205,235	D
Common Stock	11/14/2025		S		6,393(1)	D	$44.67	198,842	D
Common Stock	11/17/2025		M		6,394(1)	A	$29.62	205,236	D
Common Stock	11/17/2025		S		6,394(1)	D	$45.17	198,842	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to buy)	$29.62	11/14/2025		M			6,393(1)	03/05/2020(2)	03/05/2026	Common Stock	6,393	$0	0	D
Stock Options (Right to buy)	$29.62	11/17/2025		M			6,394(1)	03/05/2020(2)	03/05/2026	Common Stock	6,394	$0	0	D

Explanation of Responses:

1. The option exercise and subsequent sale reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2025.

2. Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was March 5, 2020.

Remarks:

	/s/ John E. Davis	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Artivion (AORT) report in this Form 4?

Artivion reported that its Chief Commercial Officer exercised stock options on two dates and sold the corresponding shares of common stock on the same days.

How many Artivion (AORT) shares were involved in the option exercises and sales?

The officer exercised options for 6,393 shares on November 14, 2025, and 6,394 shares on November 17, 2025, and sold those same numbers of shares on each date.

At what prices were the Artivion (AORT) options exercised and shares sold?

The stock options were exercised at $29.62 per share, and the resulting shares were sold at $44.67 per share on November 14, 2025, and $45.17 per share on November 17, 2025.

How many Artivion (AORT) shares does the insider own after these transactions?

Following the reported transactions, the Chief Commercial Officer directly owned 198,842 shares of Artivion common stock.

Were the Artivion (AORT) insider transactions made under a Rule 10b5-1 plan?

Yes. The filing states that the option exercises and related share sales were effected under a Rule 10b5-1 trading plan adopted on August 14, 2025.

What are the key terms of the Artivion (AORT) stock options in this Form 4?

The stock options carried an exercise price of $29.62, vested 33 1/3% per year beginning on the first anniversary of the grant date, and had a first exercisable date of March 5, 2020, with an expiration date of March 5, 2026.